The need for cardiac device implantation in patients receiving deep brain stimulation (DBS) is increasing. Despite the theoretical risk of the two systems interacting, there are no clear guidelines for cardiologists carrying out cardiac device implantation in this population. We performed a review of the literature and describe 13 case reports in which patients have both DBS and a cardiac pacemaker or ICD implanted. Except for one early study, in which an ICD shock reset the deep brain stimulator, no significant interactions have been reported. We discuss the potential interactions between DBS and cardiac devices, and provide practical advice for implanting cardiologists. We conclude that, provided that specific precautions are taken, cardiac device implantation is likely to be safe in patients with DBS.

**Keywords**
Deep brain stimulation, Parkinson’s disease, device implantation, device programming, pacemaker, ICD

Deep brain stimulation (DBS) is an expanding neurosurgical treatment for refractory neurological conditions such as Parkinson’s disease and essential tremor, with over 120,000 devices implanted worldwide. The rate of cardiac implantable electronic device (CIED) implantation is rising annually, with 739 pacemaker implants per million and 141 ICD implants per million in western Europe in 2015. There are no data in the literature on the incidence of cardiac device implantation in patients with pre-existing DBS or vice versa. However, in an ageing population, the need for cardiac device implantation in patients receiving DBS is likely to become increasingly frequent. There is a theoretical risk of interference between these two systems as well as practical issues that must be taken into consideration during the implantation procedure.

In this article, we will discuss the indications and physiology around DBS and review the evidence in the literature for CIED implantation in patients receiving DBS. We will then summarise the potential interactions and practical considerations for patients with both systems, with advice for cardiologists in managing such patients.

**Deep Brain Stimulation**
DBS is an intervention whereby electrodes are implanted through a neurosurgical procedure into stereotactically mapped brain regions, which are selected based on the indication, and connected by wires to an implanted pulse generator (IPG; Figure 1 and Figure 2). The IPG is usually situated in the left subclavicular region. Bilateral brain electrodes can be connected to either separate bilateral IPGs or to a single IPG.

Before the long-term electrode is implanted, physiological verification is carried out by passing a microelectrode into the anatomical target to record neuronal activity, and short intervals (0.5–1 second) of high-frequency test stimulation (100–300 Hz) are delivered to the awake patient intraoperatively to observe both beneficial and adverse effects. The procedure is therefore initially carried out under general anaesthesia, with sedation interrupted for microelectrode recording. Several weeks following the procedure, the IPG is programmed by a neurologist to determine the optimal settings, with voltage, amplitude and pulse width usually manipulated.

DBS is being used for increasingly wide applications. It is most commonly used for movement disorders such as Parkinson’s disease, essential tremor and dystonia when medical treatment is ineffective or causes intolerable adverse effects. It has also been used experimentally for treating psychiatric disorders (such as refractory depression and obsessive–compulsive disorder), obesity and chronic pain states. It is best established for late-stage Parkinson’s disease in patients who are levodopa sensitive, where the subthalamic nucleus or internal segment of the globus pallidus are targeted unilaterally or bilaterally. The goal in these patients is to improve their motor function and reduce their levodopa-effective dose.

The precise mechanism of DBS is debated. It is theorised that in Parkinson’s disease, DBS at a high frequency can override the pathological low-frequency, beta-wave, oscillatory activity (11–30 Hz) and start a higher rate of neuronal activity (>60 Hz) in the dopaminergic pathways, which can treat symptoms such as bradykinesia and rigidity.
Conversely, high-frequency stimulation may hold the low-frequency oscillations underlying tremor in a refractory state, thus helping to relieve this symptom.6 Hence, traditionally, a high frequency (>100 Hz) has been used, although this may be different in select patients.7

Literature Review
A systemic review of the literature was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.8 We performed a comprehensive search of major biomedical databases (including PubMed, EMBASE and AMED) using variations of the following terms: ‘deep brain stimulation cardiac pacemaker’; ‘neurostimulator cardiac pacemaker’; ‘deep brain stimulation implantable cardioverter-defibrillator’; ‘neurostimulator implantable cardioverter-defibrillator’; and ‘deep brain stimulation cardiac defibrillator’. The final search was conducted on 10 September 2018. The reference lists from the included articles were also searched. We used a focused search strategy to include all studies that referred to DBS and cardiac pacemakers or ICDs. Prior to the search, inclusion and exclusion criteria were determined. Articles were included if they were primary studies and referred to the use of DBS and pacemakers or ICDs. Articles were excluded if they were individual views, such as commentaries or letters, or if they were secondary research, such as literature reviews. Electronic abstracts were screened using the inclusion and exclusion criteria.

After applying the inclusion and exclusion criteria, we included six articles for pacemaker and DBS and eight articles for ICD and DBS. The methodology is summarised in Figure 3. The cases described in these articles are summarised in Table 1.

Current Evidence
While device manufactures have provided some guidance, there are no specific guidelines for the implantation of CIEDs in patients with DBS devices, and the evidence in the literature is limited to case reports and small cases series (Table 1).9

The first description of a CIED in a patient with DBS was by Tavernier et al. in 1999.10 The patient had bilateral DBS with IPGs in both left and right pectoral regions. An ICD was implanted in the left abdominal position for secondary prevention after a cardiac arrest. While the DBS devices did not have an impact on the ICD function, a 34 J shock from the ICD was found to completely reset both DBS devices, resulting in them reverting to the ‘off’ position.

Five further studies reported successful implantation of ICDs in patients with DBS; however, in these cases, there was no reported interaction between the devices, with DBS function continuing as normal after defibrillator threshold testing (DFT) or ICD shocks.11–15 Cases of cardiac pacemaker implantation in patients with DBS have, similarly, found no adverse interactions between the two systems.13,16–18

More recently, novel devices have been employed in patients with bilateral DBS pulse generators who require ICD or pacemaker implantation. Borgioni et al. described the implantation of a leadless
Table 1: Summary of Case Reports

| Study | No. of patients | Which device first? | PPM/ICD generator location | PPM sensing mode | DBS mode | DBS pulse generator location | Follow-up duration (months) | Interaction |
|-------|----------------|---------------------|---------------------------|-----------------|----------|---------------------------|--------------------------|------------|
| Pacemakers and DBS | | | | | | | | |
| Senatus et al. (2004) | 2 | PPM | Left SC | B | B | Bilateral AB | 22 | None |
| Capelle et al. (2005) | 6 | PPM | Right SC | B | B | Left SC | 4-48 | None |
| Tsukuda et al. (2018) | 15 | PPM | NS | B | B | Right SC | (mean 25.3) | None |
| Tejada et al. (2017) | 21 | DBS | Left Lateral (S-ICD) | N/A | Both | Right SC and AB | None | None |
| Bader et al. (2015) | 20 | DBS | Left Lateral (S-ICD) | N/A | Both | Left SC | 12 | None |
| Karimi et al. (2012) | 14 | NS | Left SC and AB | B | U | Left SC | <1 | None |
| Ooi et al. (2011) | 13 | NS | Right SC | B | NS | Left SC | 36 | None |
| Obwegeser et al. (2001) | 11 | DBS | Right SC | B | NS | Bilateral SC | 4 | None |
| Ashino et al. (2009) | 18 | DBS | Left SC | B | B | Right SC | 34 | None |
| Ooi et al. (2011) | 1 | NS | Right SC | B | B | Left SC | 14 | None |
| Bongiorni et al. (2016) | 19 | NS | Leadless PPM | B | Both | Bilateral SC | 6 | None |

ICD and DBS

Tavernier et al. (1999) | 1 | DBS | Left AB | B | Both | Bilateral SC | 1 | ICD shock reset DBS |

Obwegeser et al. (2001) | 1 | DBS | Right SC | B | Both | Left SC | 4 | None |

Rosenow et al. (2001) | 1 | DBS | Left AB | B | Both | Bilateral SC | <1 | None |

Ooi et al. (2011) | 1 | NS | Left SC | B | B | Right SC | 34 | None |

Karimi et al. (2012) | 1 | DBS | Left AB | B | Both | Bilateral SC | <1 | None |

Bader et al. (2015) | 1 | DBS | Left Lateral (S-ICD) | N/A | Both | Right SC | 12 | None |

Tejada et al. (2017) | 1 | DBS | Left Lateral (S-ICD) | N/A | U | Bilateral SC | 12 | None |

Tsuchida et al. (2018) | 1 | DBS | Left SC | NS | Both | Right SC + Left Lateral | <1 | None |

*p: p value, DBS system was followed by a PPM followed by a further DBS system.*

AB = abdominal; B = bipolar; DBS = deep brain stimulation; NS = not stated; PPM = permanent pacemaker; S-ICD = subcutaneous ICD; SC = subclavicular; U = unipolar.

Pacemaker in a patient with bilateral BDS without any reported interaction.79 Bader and Weinstock, and Tejada et al. demonstrated the successful implantation of subcutaneous ICD (S-ICD) systems in patients with BDS, again with no interference between the devices.20,21

Potential Interactions

Several practical and theoretical interactions should be taken into consideration for patients with both BDS and a cardiac device. The most concerning of these is the potential for one of the devices to impact on the activity of the other.

One study reported the complete reset of bilateral BDS devices after a shock from an implanted ICD; however, there have been no other reports of similar interactions.10 While brief interruption of BDS is unlikely to cause significant morbidity or mortality, the inhibition of a cardiac pacemaker or ICD could result in syncope or sudden cardiac death. ECG artefacts have been reported in patients with BDS, again with no interference between the devices.20,21

Capelle et al. demonstrated that changing the atrial sensing configuration of a cardiac pacemaker from unipolar to bipolar significantly reduced the intracardiac ECG artefact from a unipolar BDS system, though neither configurations resulted in inappropriate atrial sensing.19 The vast majority of modern CIEDs are programmable to bipolar sensing, but this is an important consideration for patients with older devices. There are no reported cases in the literature where a patient with a BDS device has a cardiac device using unipolar sensing configuration. S-ICDs have much larger bipole for sensing compared to transvenous systems; however, two cases demonstrated no evidence of inappropriate sensing in patients with BDS.20,21

DBS systems can also be programmed to either unipolar or bipolar mode. When in bipolar mode, the circuit is small and limited to the electrode implanted in the brain. In unipolar mode, the circuit is much larger, running from the brain electrode down to the IPG in the chest. It is generally recommended that both the cardiac device and BDS device are set to bipolar mode, and it has been shown that doing so eliminates any interference on both the surface and intra-cardiac ECG.15,16,23 The setting of the BDS, however, depends on the requirements of the patient, and can change the efficacy of the treatment, with some patients requiring unipolar configuration for optimal symptom control. Unipolar configuration of a BDS system has been reported along with a CIED without any significant interference.15-17,19,14,17-23

A further precaution to take is to ensure there is an adequate distance between the generators of BDS and cardiac devices. Medtronic
Pacemaker and Defibrillator Implantation and Programming

ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW

2. National Institute of Cardiovascular Outcomes Research.

1. Hamani C, Florence G, Heinsen H, et al. Subthalamic nucleus deep brain stimulation: basic concepts and novel perspectives. eLinus; 2017-4.psi/ENENEURO.0140-17.2017; https://doi.org/10.1523/ENENEURO.0140-17.2017; PMID: 28964978.

3. National Institute of Cardiovascular Outcomes Research. National Audit of Cardiac Rhythm Management Devices: April 2015–March 2016. London: NICOR; 2017. Available at: www.ucl.ac.uk/nicro/audits/cardiacrhythm/documents/annual-reports/

4. Hutchison W. Microelectrode recording and microstimulation of the DBS system. In: Bain P, Aziz T, Liu X, Nandi D, editors. Deep Brain Stimulation. 1st ed. Oxford: Oxford University Press; 2009.6.

5. Benabid A, Chabardes S, Lebas J. Subthalamic nucleus deep brain stimulation in Parkinson’s disease. In: Bain P, Aziz T, Liu X, Nandi D, editors. Deep Brain Stimulation. 1st ed. Oxford: Oxford University Press; 2009.6.

Table 2: Steps to Minimise Issues During Deep Brain Stimulation and Cardiovascular Implanted Electronic Device Implantation

- Multidisciplinary team approach with neurology input.
- Implant cardiac device on the contralateral side to the implanted pulse generator.
- Ensure there is at least 20 cm between the two generators.
- Use bipolar sensing configuration for the cardiac device.
- Ideally, use bipolar deep brain stimulation settings with a minimum frequency of 60 Hz.
- Consider leadless pacemaker in patients with bilateral IPGs.
- Avoid diathermy during cardiovascular implantable electronic device implantation.
- Programme devices for ‘worst case scenario’ settings during testing.

There has been a case report of severe central nervous system damage secondary to an interaction between diathermy and DBS.27 It is therefore wise to avoid diathermy in patients with DBS systems. If diathermy is absolutely required, options include turning off the DBS device before the procedure or ensuring bipolar diathermy is used.

Conclusion

While the reports of cardiac pacemaker or ICD implantation in patients with DBS are limited, the evidence suggests that both systems can be implanted without significant interaction, provided that certain precautions are taken.

Patients receiving DBS who require CIED implantation should be managed in a multidisciplinary setting with input from neurologists to optimise DBS settings prior to the procedure. Several practical steps can be taken by the cardiologist to minimise the risk of interference (Table 2).

Since the published outcome data in patients with cardiac devices and DBS is limited to case reports, it is possible that significant interactions are under-reported. A large, prospective, observational study is needed in this patient population to more clearly assess safety and accurately determine the risk of complications and interaction between cardiac devices and DBS.

Clinical Perspective

- Cardiac devices can be safely implanted in patients receiving deep brain stimulation (DBS) provided that certain precautions are taken.
- Patients should be managed with a multidisciplinary approach including neurology input.
- Cardiac device generators and DBS implantable pulse generators should be implanted on contralateral sides with >20 cm distance between them.
- Both the cardiac and DBS systems should be in bipolar configuration.

1. Hanami C, Florence G, Heinsen H, et al. Subthalamic nucleus deep brain stimulation: basic concepts and novel perspectives. eLinus; 2017-4.psi/ENENEURO.0140-17.2017; https://doi.org/10.1523/ENENEURO.0140-17.2017; PMID: 28964978.

2. National Institute of Cardiovascular Outcomes Research. National Audit of Cardiac Rhythm Management Devices: April 2015–March 2016. London: NICOR; 2017. Available at: www.ucl.ac.uk/nicro/audits/cardiacrhythm/documents/annual-reports/
Drugs and Devices

7. Obwegeser AA, Uitti RJ, Turk MF, et al. Simultaneous thalamic deep brain stimulation frequency on upper limb motor function in Parkinson’s disease. J Parkinsons Dis 2018;8:267–71. https://doi.org/10.3233/JPD-171150; PMID: 29614696.

8. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009:e1000097. https://doi.org/10.1371/journal.pmed.1000097; PMID: 19620722.

9. Medtronic. Guidelines for patients who require both pacemaker and neurostimulator. http://manuals.medtronic.com/content/dam/emanuals/neuro/M927893A064A_view.pdf (accessed April 23rd, 2019).

10. Tavernier R, Fonteyne W, Vandewalle V, et al. Use of an implantable cardioverter defibrillator in a patient with two implanted neurostimulators for severe Parkinson’s disease. Pacing Clin Electrophysiol 2005;28:1052–9. https://doi.org/10.1111/j.1540-8159.2000.tb00899.x; PMID: 10879397.

11. Ooi Y, Falowski S, Wang D, et al. Simultaneous use of neurostimulators in patients with a preexisting cardiovascular pacemaker and neurostimulator. http://manuals.medtronic.com/content/dam/emanuals/neuro/M927893A064A_view.pdf (accessed April 23rd, 2019).

12. Rosenow JM, Tarkin H, Zias E, et al. Simultaneous use of bilateral subthalamic deep brain stimulator and an implantable cardioverter-defibrillator. Mayo Clin Proc 2001;76:87–9. https://doi.org/10.4065/76.1.87; PMID: 11155420.

13. Capelle H, Simpson KJ, Krumbenburger M, et al. Long-term deep brain stimulation in elderly patients with cardiac pacemakers. J Neurosurgery 2005;102:53–9. https://doi.org/10.3171/jns.2005.102.1.0053; PMID: 15668096.

14. Ashino S, Watanabe I, Okumura Y, et al. Implantation of a permanent pacemaker in a patient with severe Parkinson’s disease and a pre-existing deep brain stimulator. H Heart J 2006;47:803–10. https://doi.org/10.1536/hj.47.803 PMID: 17165151.

15. Auhina S, Watanabe I, Okumura Y, et al. Implantation of a pacemaker in a patient with severe Parkinson’s disease and a pre-existing deep brain stimulator. Jpn Heart J 2014;58:461–3. https://doi.org/10.1093/heartjnl/jhu014; PMID: 25197118.

16. Khan I. Differential electrocardiographic artifact from implanted thalamic stimulator. Indian J Anaesth 2014;58:285–6. https://doi.org/10.1016/j.ija.2014.09.002; PMID: 2526047.

17. Senatus P, McClelland S, Ferris A, et al. Implantation of bilateral deep brain stimulators in patients with Parkinson disease and preexisting cardiac pacemakers. Report of two cases. J Neurosurgery 2004;101:1053–7. https://doi.org/10.3171/jns.2004.101.6.1053; PMID: 15797774.

18. Sharma M, Talbott D, Dziganzionk M. Interaction between cardiac pacemakers and deep brain stimulation pulse generators: technical considerations. Anaesth Intensive Care 2014;42:19–22. https://doi.org/10.1111/aia.12101.

19. Davies R. Deep brain stimulation and anaesthesia. Br J Anaesth 2005;95:424. https://doi.org/10.1093/bja/ael879; PMID: 16706204.

20. Khetarpal M, Yadav M, Kulkarni D, Gopinath R. Anaesthetic management of a patient with deep brain stimulation implant for radical nephrectomy. Indian J Anaesth 2014;58:461–3. https://doi.org/10.4103/0019-5049.139909; PMID: 25197118.

21. Nutt J, Anderson V, Peacock J, et al. Cardiac resynchronization therapy–defibrillator in a patient with bilateral pectoral deep brain stimulators. HeartRhythm Case Rep 2017;3:109–12. https://doi.org/10.1016/j.hrscr.2017.12.005; PMID: 29750476.

22. Tsekos KV, Mostbeck G, Anderson VE, et al. Successful implantation of a subcutaneous cardiac defibrillator in a patient with a preexisting deep brain stimulator. Europace 2015;17:2141–4. https://doi.org/10.1093/europace/euv195; PMID: 26491558.

23. Bader Y, Weinstock J. Successful implantation of a subcutaneous cardiac defibrillator in a patient with a preexisting deep brain stimulator. HeartRhythm Case Rep 2015;1:241–4. https://doi.org/10.1016/j.hrscr.2015.03.014; PMID: 26491558.